Drug Approval | May 14, 2025
Briefs: Zydus and CuraTeQ Biologics
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The product will be launched in Q1FY26
The company does not expect this development to have any material impact on the current business operations
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Subscribe To Our Newsletter & Stay Updated
